Pfizer bristles at calls for trial transparency; Targacept vet takes the helm at Faraday;

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Looking forward to an upcoming panel discussion on organ-on-a-chip tech. And you can't beat the price. More | Follow @JohnCFierce

@DamianFierce: Look at this idiot thing I wrote last year. Article | Follow @DamianFierce

> Novartis ($NVS) has launched the U.S.'s first biosimilar, marketing a copy of Amgen's ($AMGN) Neupogen at a 15% discount after months of legal wrangling. More

> Former Targacept CEO Stephen Hill has taken the top spot at Faraday Pharmaceuticals, a biotech upstart developing treatments for critical care. More

> Pfizer ($PFE) is pushing back against investors calling for the company to release full trial results from past studies, arguing that doing so would provide little benefit to patients. Story

Medical Device News

@FierceMedDev: Updated w/ company comment: Merck, Daktari collaborating on hep C diagnostic. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: HeartWare looks diversify into mitral valve repair with $929M purchase of Valtech Cardio. Article | Follow @VarunSaxena2

@EmilyWFierce: European pharma lobby says 'non' to French funding for off-label Avastin. ICYMI fron FiercePharma | Follow @EmilyWFierce

> Stratasys launches 3-D printer for production of dental devices. Story

> Valeant to buy microsurgery tools company Synergetics for up to $190M. Article

Pharma News

@FiercePharma: China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. FiercePharmaAsia article | Follow @FiercePharma

@CarlyHFierce: ICYMI: AstraZeneca sales team revving up for new Brilinta marketing push. More | Follow @CarlyHFierce

> Novartis' LCZ696 scores another victory with early-access blessing in U.K. More

> UCB hands off U.S. generics business to Lannett for $1.23B. Story

Vaccines News

> Daiichi Sankyo inks deal to market AstraZeneca's FluMist in Japan. More

> Cornell grad looks to change the way parents remember vaccine schedules. Report

> GlaxoSmithKline signs on LimmaTech for vaccine R&D. Story

> NHS meningitis B vaccination scheme begins in U.K. Item

> BiondVax pairs with NIAID to test universal flu vaccine in U.S. PhII. Article

CRO News

> PPD partners up to better track trial events. News

> WuXi looks to Japan for manufacturing growth. Report

> BioClinica opens an app umbrella to unite researchers. More

> Chinese drugmaker trades $200M for CDMO Cytovance. Story

> AMRI signs on to help Saneca develop opium-based drugs. Article

Pharma Manufacturing News

> Sun gets direct line to poppy production with buyout of GSK opiates biz. Report

> Lannett manufacturing capacity balloons to 522,000 sq. ft. in short order. Story

> China poaches Indian scientists to build formulation expertise. News

> Novo building huge warehouse to support production expansion. Item

> Sun recalls yet another med made at troubled Halol plant. Report

Pharma Asia News

> Pharma market bets on ASEAN in focus ahead of economic pact. Story

> HK's Medisun, Belgium's Celyad revise C-Cure pact for Greater China. Item

> China's Ascletis gets Taiwan nod for PhII trial of interferon-free HCV candidate. Report

> GSK hep B supplies to Japan hit by Tianjin explosion. Story

> Abbott touts Japan drug-eluting Absorb stent trial results, but no approval timeline. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.